ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: Bogardus Heads ASTRO, Million President Elect; Woods Named Chief of NIC Contracts Review

October 27, 1989

Text of PDQ Statement on Breast Screening

September 17, 1993

Wynder Group Finds No Association Between Coffee, Pancreatic Cancer

August 19, 1983

NCCS Networker Volume 2 Issue 2, Spring 1988

April 13, 1988

HHS System Of Misconduct investigation Not Suited For Clinical Trials, Broder Says

November 11, 1994

Commentary: NCI’s Budge Proposal ForFY2001 Offers A Blueprint for Research

November 26, 1999